

**Supplementary figure 4.** **Monocyte phenotyping in patients with uveitis before and during treatment with adalimumab and in healthy controls.**

w0: patients before initiation of adalimumab treatment; w6: patients after 6 weeks of adalimumab treatment; w12: patients after 12 weeks of adalimumab treatment. Percentage of cells positive for both CD14 and one additional surface marker, and level of expression of respective surface markers on CD14+ cells (mean fluorescence intensity, MFI).